Firebrick Pharma Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRE.AX research report →
Price Chart
About the company
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
- CEO
- Peter Laurence Molloy
- IPO
- 2022
- Employees
- 6
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on FRE.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.46M
- P/E
- -2.55
- PEG
- 0.07
- P/S
- 16.92
- P/B
- 3.39
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
- Gross Margin
- -68.29%
- Op Margin
- -612.99%
- Net Margin
- -642.18%
- ROE
- -140.26%
- ROIC
- -119.27%
Latest fiscal year · YoY change
- Revenue
- $293.42K+1920.5%
- Gross Profit
- $104.82K+560.1%
- Op Income
- $-2,865,694
- Net Income
- $-2,634,428-124.0%
- EPS
- $-0.01-89.4%
- OCF Growth
- +24.1%
- FCF Growth
- +20.6%
- 52W High
- $0.08
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.05
- Beta
- 0.85
- RSI (14)
- 45
- Avg Volume
- 280.32K
No earnings-call transcripts are available for FRE.AX yet.
- Free Float
- 59.3%
- Shares Outstanding
- 239.18M
- Float Shares
- 141.91M
Our FRE.AX coverage
Recent articles, reports, and earnings notes.
No research on FRE.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FRE.AX report →